{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-050775","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2026-07-30T11:03:02+00:00","discovered_at":"2026-07-30T11:05:00.323916+00:00","generated_at":"2026-07-30T11:05:50.400510+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Madrigal Q2 Rezdiffra sales $364.3M (+71% YoY); net loss $57.9M","bullets":["Rezdiffra net sales $364.3M, up 71% from $212.8M in Q2 2025; over 49,000 patients on therapy as of June 30, 2026.","Net loss $57.9M ($1.99/share) vs. $42.3M ($1.50/share) a year ago; includes $25M one-time business development expense.","Cash and marketable securities $838.9M as of June 30, 2026, down from $988.6M at Dec. 31, 2025.","Three new resmetirom patents issued, including one for F4c (well-compensated cirrhosis) with protection into 2042.","MGL-2086 (oral GLP-1) Phase 1 SAD trial initiated in June 2026 for Rezdiffra combination program in MASH."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-050775","json":"https://secwatch.observer/filing/0001628280-26-050775.json","markdown":"https://secwatch.observer/filing/0001628280-26-050775.md","text":"https://secwatch.observer/filing/0001628280-26-050775.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/0001628280-26-050775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/mdgl-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T11:05:50.400510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}